Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib Dose-Optimization Study in Myelofibrosis
NCT03886415Phase 2Completed
- Sponsor
- Zelgen
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of jaktinib in myelofibrosis (MF) (2 arms), sponsored by Zelgen. Primary endpoint: Proportion of patients with >=35% reduction in spleen volume at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03886415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886415.